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Abstract
Background: Adenocarcinoma of the pancreas only rarely is associated with inflammatory myopathy. In this
setting, polymyositis may be treated with glucocorticoids in combination with cancer specific treatment.
Case presentation: We present the case of a 52-year-old man with stage IIA pancreatic tail adenocarcinoma who
underwent surgical treatment and six months into therapy with gemcitabine he developed symmetrical, painful,
proximal muscle weakness with peripheral oedema. Re-evaluation with imaging modalities, muscle histology and
biochemistry conferred the diagnosis of polymyositis associated with pancreatic cancer progression. The patient
was treated with glucocorticoids along with gemcitabine and erlotinib which resulted in complete remission
within six months. He remained in good health for a further six months on erlotinib maintenance therapy when a
new computer tomography scan showed pancreatic cancer relapse and hence prompted 2
nd line chemotherapy
with gemcitabine.
Conclusions: Polymyositis associated with pancreatic cancer may respond to glucocorticoids along with cancer
specific treatment.
Background
In developed countries, pancreatic adenocarcinoma is
the fourth leading cause of cancer death, with an overall
5-year survival rate of less than 10% [1] and the inci-
dence appears to be increasing. Despite the advances in
chemotherapy, particularly gemcitabine, and the devel-
opment of new tyrosine kinase inhibitors, such as erloti-
nib (Tarceva) an epidermal growth factor receptor
(EGFR) inhibitor, the prognosis for patients with pan-
creatic cancer is dismal[1].
An association between malignancy and inflammatory
myopathy was suspected as early as 1916, with adeno-
carcinomas of the cervix, lung, ovaries, pancreas, blad-
der, and stomach accounting for approximately 70
percent of the cancers associated with inflammatory
myopathies[2]. On the other hand, patients with
inflammatory myopathies, which commonly include der-
matomyositis and polymyositis, have a clearly higher
risk of cancer than the general population. Moreover,
when inflammatory myopathies present with a signifi-
cant weakness at diagnosis, they carry an unfavorable
impact on prognosis[2-4].
Herewith we present a case of polymyositis complicat-
ing the physical history of a patient with pancreatic ade-
nocarcinoma on treatment with gemcitabine who
responded well to glucocorticoids along with cancer spe-
cific treatment.
Case presentation
In March 2009, a 52-year-old Caucasian man, smoker
30 pack/y, with type II diabetes presented with a recent
history of recurrent acute pancreatitis and significant
weight loss (15 kg over 3 mo). Computer Tomography
(CT) examination revealed a solitary mass lesion in the
pancreatic tail and the patient subsequently underwent
distal pancreatectomy coupled with splenectomy. Patho-
logic examination of the resected specimens conferred
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which was locally invasive to the peripancreatic adipose
tissue. Lymph nodes were negative and surgical margins
were clear (T.N.M. stage IIA). The patient was treated
with sequential adjuvant chemotherapy, six cycles of
gemcitabine (1000 mg/m2) on days 1, 8, 15 and every
28 d with a steady decline of CA 19.9 levels. Six months
into treatment with gemcitabine he developed symmetri-
cal, painful, proximal muscle weakness in the upper and
lower limbs with peripheral oedema and significant
pain. The symptoms were severe enough to have con-
fined him to a wheelchair.
On readmission to hospital physical signs and history
suggested the diagnosis of polymyositis. Aspartate ami-
notrasferase (AST) was 103 U/L (normal 5-40), alanine
aminotrasferase (ALT) 77 U/L (normal 5-40), creatinine
kinase (CK) 595 U/L (normal 40-150), lactate dehydro-
genase (LDH) 556 U/L (normal 200-460), C-reactive
protein (CRP) 560 nmol/L (normal <47.6); troponin I
was negative. A repeat CT scan was performed which
was demonstrated some alterations in the density of the
mesenteric fat (misty mesentery) suggestive of pancrea-
tic cancer progression. Soft tissue ultrasound examina-
tion of his left forearm flexors and right major pectoral
muscle, showed findings consistent with myositis. Anti-
neural antibodies were negative and sensory neuropathy
was excluded by nerve conduction velocity testing. Elec-
tromyographic findings revealed a myopathic pattern
with spontaneous activity. Biopsy of the right quadriceps
muscle showed diffuse degenerative changes along with
lymphocytic infiltrate and angular fibers. There was also
thickening of the fibrous connective tissue septa and
foci of fat infiltration; all the above findings were sug-
gestive of myositis (Figure 1). Immunohistochemical
stainining for CD8 expressing lymphocytes revealed
sparse infiltrates of intramysial CD8-positive cells
(brown diaminobenzidine staining). (Figure 2).
Intravenous methylprednisolone was initiated at a
dose of 125 mg daily for two days and then was imme-
diately switched to oral methylprednisolone 16 mg daily.
A dramatic clinical response was observed shortly after
treatment with glucocorticoids and the patient became
fully ambulatory. Erlotinib 100 mg daily was started on
standard gemcitabine based chemotherapy. Following
his discharge, treatment with methylprednisolone 16 mg
daily on tapering dose was continued for six months
along with gemcitabine and erlotinib with complete
remission of polymyositis. Re-evaluation by computed
tomography (CT)-positron emission tomography-com-
puted tomography (PET/CT) of the abdomen at that
stage showed complete cancer remission (Figure 3).
Chemotherapy was ceased along with corticosteroids
and the patient remained on treatment with mainte-
nance erlotinib remaining in good health and leading an
active life. Unfortunately twelve months following his
discharge a repeat CT scan showed pancreatic cancer
relapse and prompted 2
nd line chemotherapy with gem-
citabine. Interestingly, the progressive malignant disease
was not followed by a myositis relapse.
Discussion
Cancer of the pancreas is associated with several para-
neoplastic syndromes. Polymyositis/dermatomyositisis is
an inflammatory connective tissue disease predominantly
involving skeletal muscle and is strongly associated with
Figure 1 Histological findings of muscle biopsy.M u s c l eb i o p s y
showing diffuse degenerative changes with angular fibers (arrows)
and variation in muscle fiber size. Mononuclear inflammatory cells
consisting of lymphocytes are present, surrounding individual non
necrotic fibers (arrowhead). Some foci of fat infiltration and
connective tissue septa thickening can also be seen. H&E stain, 100
× original magnification.
Figure 2 CD8 immunohistochemical staining. Immunohistochemical
stainining for CD8 expressing lymphocytes. Arrows are indicating
sparse infiltrates of intramycial CD8-positive cells. Brown
diaminobenzidine staining, 200 × original magnification).
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914 cases of polymyositis had cancer, and reported that
the standardized incidence ratio - SIR was 1.4 (95% CI
1.0-1.8) for men and 1.2 (0.9-1.6) for women. Polymyosi-
tis was associated with a raised risk of non-Hodgkin lym-
phoma, lung and bladder cancers, but not of pancreatic
cancer. Sigurgeirsson et al[2] further sustained that
inflammatory myopathy is strongly associated with
malignancy and the malignant diseases most associated
with inflammatory myositis were, in descending order:
lung cancer, rectum and colon cancer, pancreatic cancer,
kidney cancer, stomach cancer, breast cancer and Car-
penter et al[3] reported poor prognosis when significant
weakness is experienced at presentation.
Our patient was diagnosed with high grade, pancrea-
tic-tail adenocarcinoma and six months following diag-
nosis and surgical resection, presented with proximal
symmetrical muscle weakness, myalgias and generalised
oedema while on treatment with gemcitabine. These
signs were alarmingly suspicious of inflammatory myo-
pathy and prompted further specific investigations.
Eventually, diagnosis was confirmed with blood bio-
chemistry, electromyography and muscle histology on
the basis of a highly compatible history and physical
findings.
According to Bohan and Peter’s criteria[5], polymyosi-
tis is an inflammatory myopathy with no rash. It is
defined by symmetric proximal muscle weakness, ele-
vated serum muscle enzymes, myopathic changes on
electromyography, characteristic muscle biopsy abnorm-
alities and the absence of histopathologic signs of other
myopathies. Muscle weakness is indeed the most com-
mon presenting feature of polymyositis. The onset is
usually insidious and the distribution of weakness is
typically symmetric and proximal. Myalgias occurs in
less than 30% of the patiens[7].
Serum muscle enzyme levels are usually elevated in
patients with polymyositis including CK, LDH, aldolase,
AST and ALT which are routinely measured in the eva-
luation of myopathy. Although most patients with poly-
myositis have increased CK levels, reported series
include patients with normal CK levels at presentation
[8]. Specific autoantibodies such as those directed
against cytoplasmic RNA synthetases, other cytoplasmic
proteins, ribonucleoproteins, and certain nuclear anti-
gens play important role in the assessment of patients
with polymyositis given that they occur in approximately
30 percent of patients with polymyositis[9]. In addition
to these, a novel autoantibody to a 155 kd protein (anti-
p155) is commonly found in cancer associated dermato-
myositis, but not in cancer associated polymyositis[10].
Even in clinical scenarios consistent with polymyositis,
muscle biopsy is essential to establish the diagnosis.
Typically, the cellular infiltrate is predominantly within
the fascicle with inflammatory cells invading individual
muscle fibers. Abnormal muscle fibers are scattered
throughout the fascicle. Furthermore, there is evidence
of cell-mediated immune mechanisms with presence of
cytotoxic CD8+ T cells, which recognize antigens on the
muscle fiber surface, and enhanced expression of major
histocompatibility complex (MHC) antigens by the mus-
cle fibers[11].
Although the scenario of gemcitabine induced myosi-
tis cannot be entirely excluded in our case, this appears
to be highly unlikely; we found just one case report in
the literature[12] implicating gemcitabine given along
with docetaxel in inflammatory myopathy in a patient
with lung adenocarcinoma and nevertheless as myositis
in our patient heralded disease progression, it was fair
to assume that it was disease rather than drug induced
and thus necessitated standard immunosuppressive
treatment along with cancer specific therapy. Subse-
quently, a dramatic clinical response was observed and
the patient was ambulatory and fully recovered. Bio-
chemical parameters normalised shortly after treatment
with intravenous glucocorticoids and maintenance treat-
ment with oral corticosteroids coupled with gemcitabine
and erlotinib conferred complete response.
Glucocorticoids are indeed the cornerstone of initial
therapy for polymyositis but in severely ill patients,
azathioprine or methotrexate is preferable. The treat-
ment of choice is prednisone in tapering doses for
approximately one year, depending upon patient’s
Figure 3 Abdominal PET/CT. Figure 2. PET/CT fusion image taken
six months into treatment with erlotinib and corticosteroids
showing postoperative findings only. There is no increased uptake
of
18F-FDG.
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Nevertheless, as many as 50% of patients with polymyo-
sitis do not respond to glucocorticoid therapy alone
[2,13]. However in paraneoplastic polymyositis it is diffi-
cult to evaluate whether the clinical response of myositis
is due to glucocorticoids per se or to the concurrent use
of immunosuppressive chemotherapy or due to a syner-
gistic effect among them.
Giving an insight in the pancreatic tumor cell, there
are several immunogenic tumor antigens to elicit cellu-
lar as well as humoral immunity. In the Okada et al
study[14], two DNA mismatch repair enzymes, Homo
sapiens mutS homolog 2 (hMSH2) and Homo sapiens
postmeiotic segregation increased 1 (hPMS1) were
found to over-express in pancreatic ductal adenocarci-
noma, and their antibodies were detected in sera from
patients with pancreatic ductal adenocarcinoma, and in
sera from patients with polymyositis, but not in sera
from healthy individuals. Therefore, hMSH2 and hPMS1
could be immunogenic antigens in patients with pan-
creatic adenocarcinoma. Additionally Egberts et al
showed that dexamethasone treatment had profound
influence of pancreatic duct adenocarcinoma cells in
vitro in terms of inhibition of invasiveness and activation
of NFB which was approved in vivo by reduced metas-
tasing capability and reduced size of local tumour recur-
rence in an experimental model of pancreatic cancer
[15]. These observations indicate that the link between
malignancy and inflammatory myopathy relates possibly
to the expression of common autoantigens between can-
cer tissue and muscle tissue in some patients with poly-
myositis. From a therapeutic point of view treatment
with glucocorticoids should be justified in confirmed
cases of polymyositis associated with pancreatic cancer
along with cancer specific therapy. In addition our
experience reinforces the basis for adjuvant immu-
notherapy as a potential additional therapeutic modality
for all patients with pancreatic cancer, a notion which
has been based mainly on experimental findings but
appears to collect clinical substantiation and certainly
merits further investigation.
Conclusions
Polymyositis is a paraneoplastic syndrome which may be
encountered in patients with pancreatic cancer causing
significant morbidity. Clinicians should be aware of this
syndrome as it may manifest at any stage during the
physical history of pancreatic cancer. In this clinical set-
ting a trial with corticosteroids along with cancer speci-
fic treatment may be of benefit.
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